Extraction-free sensitive detection of viral RNA using direct RT-PCR chemistry

Nucleic acid amplification tests (NAAT) are a reliable, sensitive, and accurate diagnostic approach used in viral detection. The approach involves the isolation of nucleic acids from a sample, which is not only time and resource consuming but increases the chances of accidental contamination and human error. In a period of high demand, such as the COVID-19 pandemic, treatment, monitoring, successful management and control relies on the rapid and accurate detection of viral pathogens.

Direct reverse transcriptome polymerase chain reaction (RT-PCR) from unpurified samples promises to reduce the time and resources required for sample testing by eliminating the need for the isolation of nucleic acids. This webinar provides an overview of the technical limitations of this approach and provides an overview of a proprietary chemistry that helps to overcome challenges with sample degradation and sensitivity levels in the detection of viral particles.

Learning Objectives
• Understand reverse transcription quantitative PCR (RT-qPCR) technology and growth potential
• Review the opportunities and challenges for extraction-free methods
• Discuss a robust extraction-free chemistry optimized for One-Step RT-qPCR for detection of RNA.

Speakers:

Donald Green
MSc Biomed Engr, MSc Neuroscience
Senior Field Application Specialist, Genomics and Diagnostics, Cytiva
Donald has worked in a variety of disciplines related to the field of molecular research. He began his research career in Biomedical Engineering at Mississippi State University and later in Neuroscience studying Autism Spectrum Disorders at the University of Mississippi Medical Center. Over the past eleven years, he has worked in the research industry for well-established life sciences organizations in several roles, including, Field Engineering Specialist, Field Application Specialist, and Clinical Application Specialist. Along his varied path he has gained experience in clinical diagnostics, lab developed tests, and helping develop start-ups focused on Next Generation Sequencing (NGS) using targeted sequencing for Oncology.